🔥🐔 BizChicken 🐔🔥

Companies Similar to Phathom Pharmaceuticals, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: High

ONPATTRO

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. It targets genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases.

Tags: CNS diseases, RNAi therapeutics, biopharmaceutical, cardio-metabolic diseases, genetic medicines, hepatic diseases

Symbol: ALNY

Recent Price: $236.01

Industry: Biotechnology

CEO: Dr. Yvonne L. Greenstreet M.B.A., MBChB

Sector: Healthcare

Employees: 2100

Address: 675 West Kendall Street, Cambridge, MA 02142

Phone: 617 551 8200

Leadership

  • Yvonne Greenstreet, Chief Executive Officer
  • Pushkal Garg, Chief Medical Officer
  • Jeff Poulton, Chief Financial Officer
  • Kelley Boucher, Chief Human Resource Officer
  • Timothy Maines, Chief Technical Operations and Quality Officer
  • Tolga Tanguler, Chief Commercial Officer
  • Piyush Sharma, Chief Ethics & Compliance Officer
  • Evan Lippman, Chief Corporate Development & Strategy Officer
  • Kevin Fitzgerald, Chief Scientific Officer
  • Amy W. Schulman, Chair
  • Dennis A. Ausiello,
  • Carolyn Bertozzi,
  • Michael W. Bonney,
  • Olivier Brandicourt,
  • Margaret A. Hamburg,
  • Peter N. Kellogg,
  • David E.I. Pyott,
  • Colleen F. Reitan,
  • Phillip A. Sharp,
  • Elliott Sigal,

Last updated: 2024-12-31

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TNX-103, TNX-102 (levosimendan), TNX-201 (imatinib)

Tenax Therapeutics, Inc. is a specialty pharmaceutical company that focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases. The company is involved in developing medications such as TNX-103 and TNX-102 (levosimendan) for pulmonary hypertension and heart failure, and TNX-201 (imatinib) for pulmonary arterial hypertension.

Tags: TNX-102, TNX-103, TNX-201, cardiovascular, pharmaceutical, pulmonary diseases

Symbol: TENX

Recent Price: $6.55

Industry: Biotechnology

CEO: Mr. Christopher T. Giordano

Sector: Healthcare

Employees: 5

Address: ONE Copley Parkway, Morrisville, NC 27560

Phone: 919 855 2100

Last updated: 2024-12-31

Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. logo
Market Cap: Low
Employees: Low

HETLIOZ, Fanapt

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for high unmet medical needs, including marketed products like HETLIOZ for sleep-wake disorders and Fanapt for schizophrenia, with ongoing development for other conditions.

Tags: Fanapt, HETLIOZ, biopharmaceutical, schizophrenia, sleep disorders, therapies

Symbol: VNDA

Recent Price: $4.78

Industry: Biotechnology

CEO: Dr. Mihael H. Polymeropoulos M.D.

Sector: Healthcare

Employees: 203

Address: 2200 Pennsylvania Avenue NW, Washington, DC 20037

Phone: 202 734 3400

Last updated: 2024-12-31

VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

PH94B

Vista Gen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for anxiety, depression, and other CNS disorders. Their CNS pipeline includes PH94B and PH10, rapid-onset neuroactive nasal sprays for anxiety and depression, respectively.

Tags: AV-101, CNS disorders, PH10, PH94B, anxiety treatment, biopharmaceutical, depression treatment

Symbol: VTGN

Recent Price: $2.81

Industry: Biotechnology

CEO: Mr. Shawn K. Singh J.D.

Sector: Healthcare

Employees: 41

Address: 343 Allerton Avenue, South San Francisco, CA 94080

Phone: 650 577 3600

Leadership

  • Ann Cunningham, MBA, Director
  • Joanne Curley, Ph.D., Director
  • Maggie FitzPatrick, Chair of the Board
  • Jerry Gin, Ph.D., MBA, Director
  • Mary L. Rotunno, J.D., Director
  • Jon S. Saxe, J.D., LL.M, Director
  • Shawn K. Singh, J.D., Chief Executive Officer and Director

Last updated: 2024-12-31

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

Sympazan, Suboxone, Zuplenz, Azstarys, Libervant, Exservan

Aquestive Therapeutics, Inc. is a pharmaceutical company committed to identifying, developing, and commercializing innovative products to address unmet medical needs, both in the U.S. and globally. It specializes in oral soluble film formulations for various treatments, including neurological conditions and opioid dependence.

Tags: ADHD, ALS, biotechnology, neurology, opioid dependence, oral soluble film, pharmaceutical

Symbol: AQST

Recent Price: $3.52

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Daniel Barber

Sector: Healthcare

Employees: 135

Address: 30 Technology Drive, Warren, NJ 07059

Phone: 908 941 1900

Last updated: 2024-12-31

Ardelyx, Inc.

Ardelyx, Inc. logo
Market Cap: High
Employees: Low

tenapanor

Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for gastrointestinal and cardiorenal therapeutic areas, including treatments for irritable bowel syndrome with constipation and hyperphosphatemia.

Tags: CKD, biopharmaceutical, cardiorenal, gastrointestinal, hyperkalemia, hyperphosphatemia, metabolic acidosis, tenapanor

Symbol: ARDX

Recent Price: $5.25

Industry: Biotechnology

CEO: Mr. Michael G. Raab

Sector: Healthcare

Employees: 267

Address: 400 Fifth Avenue, Waltham, MA 02451

Phone: 510 745 1700

Leadership

  • Justin Renz, Chief Financial & Operations Officer
  • Eric Foster, Chief Commercial Officer
  • Elizabeth Grammer, Esq., Chief Legal & Administrative Officer
  • Laura Williams, MD MPH, Chief Medical Officer
  • Robert Blanks, MS RAC, Chief Regulatory Affairs & Quality Assurance Officer
  • David Rosenbaum, PhD, Chief Development Officer
  • Mike Kelliher, Executive Vice President, Corporate Development and Strategy
  • Charon Spencer, Chief Human Resources Officer
  • David Mott, Chairman
  • Robert Bazemore, Director
  • William A. Bertrand, Jr., JD, Director
  • Muna Bhanji, R.Ph, Director
  • Onaiza Cadoret-Manier, Director
  • Mike Raab, Director
  • Richard Rodgers, Director

Last updated: 2024-12-31

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CTX-009, CTX-471, CTX-8371

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.

Tags: CTX-009, CTX-471, CTX-8371, antibody therapeutics, biopharmaceutical, clinical stage, oncology

Symbol: CMPX

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

Sector: Healthcare

Employees: 32

Address: 80 Guest Street, Boston, MA 02135

Phone: 617 500 8099

Last updated: 2024-12-31

Inozyme Pharma, Inc.

Inozyme Pharma, Inc. logo
Market Cap: Medium
Employees: Lowest

INZ-701

Inozyme Pharma, Inc. is a biopharmaceutical company focused on the development of therapeutics for rare disease conditions involving abnormal mineralization, particularly targeting ENPP1 and ABCC6 deficiencies.

Tags: ABCC6, ENPP1, INZ-701, biopharmaceutical, calciphylaxis, genetic diseases, mineralization, rare diseases, therapeutics

Symbol: INZY

Recent Price: $2.82

Industry: Biotechnology

CEO: Dr. Douglas A. Treco Ph.D.

Sector: Healthcare

Employees: 59

Address: 321 Summer Street, Boston, MA 02210

Phone: 857 330 4340

Leadership

  • Doug Treco, Ph.D., CEO, Chairman of Board of Directors
  • Gayle Gironda, Senior Vice President and Chief People Officer
  • Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer
  • Soojin Kim, Ph.D., Senior Vice President and Chief Technical Operations Officer
  • Yves Sabbagh, Ph.D., Senior Vice President and Chief Scientific Officer, Chair of the Scientific Advisory Board
  • Sanjay S. Subramanian, M.S., MBA, Senior Vice President and Chief Financial Officer
  • Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer
  • Axel Bolte, MBA, Co-founder, Senior Advisor and Member of Board of Directors
  • David Thompson, M.A., M.S., Ph.D., Senior Advisor, Member of Scientific Advisory Board
  • Sarah Bhagat, Ph.D., Director
  • Reinaldo M. Diaz, MBA, Director
  • Martin Edwards M.D., MBA, Director
  • Erik Harris, MBA, Director
  • Rob Hopfner, Rph, Ph.D., MBA, Director
  • Edward Mathers, Director
  • Lynne Sullivan, MST, Director

Last updated: 2024-12-31

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. logo
Market Cap: Low
Employees: Medium

XPOVIO

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing drugs targeting nuclear export for the treatment of cancer and other diseases, with a flagship product named XPOVIO.

Tags: SINE compounds, XPO1, cancer treatment, nuclear export, oncology, pharmaceutical

Symbol: KPTI

Recent Price: $0.70

Industry: Biotechnology

CEO: Mr. Richard A. Paulson M.B.A.

Sector: Healthcare

Employees: 325

Address: 85 Wells Avenue, Newton, MA 02459

Phone: 617 658 0600

Leadership

  • Richard Paulson, President and Chief Executive Officer
  • James Accumanno, Chief Compliance Officer
  • Brian Austad, Senior Vice President, Pharmaceutical Sciences
  • Sohanya Cheng, Chief Commercial Officer and Head of Business Development
  • Lisa DiPaolo, Chief Human Resources Officer
  • Mike Mano, Senior Vice President and General Counsel
  • Michael Mason, Chief Financial Officer
  • Stuart Poulton, Chief Development Officer
  • Reshma Rangwala, Chief Medical Officer & Head of Research
  • Amama Sadiq, Senior Vice President, Global Medical and Scientific Affairs
  • Elhan Webb, Senior Vice President, Investor Relations
  • Garen Bohlin, Director
  • Barry E. Greene, Lead Director
  • Mansoor Raza Mirza, MD, Director
  • Richard Paulson, MBA, President and Chief Executive Officer
  • Christy J. Oliger, Director
  • Deepa R. Pakianathan, PhD, Director
  • Chen Schor, Director
  • Zhen Su, MD, MBA, Director

Last updated: 2024-12-31

Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Medium

vonoprazan

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases, with significant advancements in the use of vonoprazan in clinical trials.

Tags: P-CAB, biopharmaceutical, clinical trials, gastrointestinal diseases, vonoprazan

Symbol: PHAT

Recent Price: $8.00

Industry: Biotechnology

CEO: Ms. Terrie J. Curran

Sector: Healthcare

Employees: 452

Address: 100 Campus Drive, Florham Park, NJ 07932

Phone: 877 742 8466

Last updated: 2024-12-31

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. logo
Market Cap: Lowest
Employees: Lowest

INTASYL therapeutic platform

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.

Tags: ACT, BRD4, Biotechnology, Cancer, Immuno-Oncology, PD-1, TIGIT, Therapeutics

Symbol: PHIO

Recent Price: $1.90

Industry: Biotechnology

CEO: Mr. Robert J. Bitterman

Sector: Healthcare

Employees: 8

Address: 257 Simarano Drive, Marlborough, MA 01752

Phone: 508 767 3861

Last updated: 2024-12-31

Scopus BioPharma Inc.

Scopus BioPharma Inc. logo
Market Cap: Lowest
Employees: Lowest

Duet Platform

Scopus Bio Pharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics for serious diseases with lead programs in immuno-oncology gene therapy.

Tags: biopharmaceutical, cancer treatment, gene therapy, immuno-oncology, therapeutics

Symbol: SCPS

Recent Price: $0.00

Industry: Biotechnology

CEO: Dr. Alan D. Horsager Ph.D.

Sector: Healthcare

Employees: 13

Address: 420 Lexington Avenue, New York, NY 10170

Phone: 212 479 2513

Last updated: 2024-12-31

Vincerx Pharma, Inc.

Vincerx Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

VIP152

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on researching and developing therapies to address unmet medical needs for cancer treatment in the United States. Their lead product candidate, VIP152, is a cyclin-dependent kinase-9 inhibitor for advanced cancer.

Tags: biopharmaceutical, cancer treatment, clinical-stage, oncology, therapy development

Symbol: VINC

Recent Price: $0.33

Industry: Biotechnology

CEO: Dr. Ahmed M. Hamdy M.D.

Sector: Healthcare

Employees: 42

Address: 260 Sheridan Avenue, Palo Alto, CA 94306

Phone: 650 800 6676

Last updated: 2024-12-31

Viking Therapeutics, Inc.

Viking Therapeutics, Inc. logo
Market Cap: Highest
Employees: Lowest

VK2809

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, with lead drug candidate VK2809 in Phase IIb trials for non-alcoholic steatohepatitis.

Tags: VK2809, biopharmaceutical, clinical-stage, endocrine disorders, metabolic disorders, therapies

Symbol: VKTX

Recent Price: $39.77

Industry: Biotechnology

CEO: Dr. Brian Lian Ph.D.

Sector: Healthcare

Employees: 30

Address: 9920 Pacific Heights Boulevard, San Diego, CA 92121

Phone: 858 704 4660

Leadership

  • Lawson Macartney, DVM, Ph.D., Chairman
  • Matthew W. Foehr, Chief Executive Officer
  • Kathy Rouan, Ph.D.,
  • Charles A. Rowland Jr.,
  • Matthew Singleton,
  • Brian Lian, Ph.D.,

Last updated: 2024-12-31

Vor Biopharma Inc.

Vor Biopharma Inc. logo
Market Cap: Lowest
Employees: Low

VOR33

Vor Biopharma, Inc. is a clinical-stage company focused on developing engineered hematopoietic stem cell (e HSC) therapies for cancer patients, with a leading product, VOR33, in phase 1/2 trials for AML and other hematological malignancies.

Tags: AML, biotechnology, cancer therapies, e HSC, hematopoietic stem cells

Symbol: VOR

Recent Price: $1.19

Industry: Biotechnology

CEO: Dr. Robert Ang M.B.A., M.D., MBBS

Sector: Healthcare

Employees: 168

Address: 100 Cambridgepark Drive, Cambridge, MA 02140

Phone: 617 655 6580

Leadership

  • Robert Ang, MBBS, MBA, President and Chief Executive Officer
  • Eyal Attar, MD, Chief Medical Officer
  • Tirtha Chakraborty, PhD, Chief Scientific Officer
  • Han Choi, MD, LLM, Chief Financial Officer
  • John King, MBA, Chief Commercial Officer and Head of Business Development
  • Tania Philipp, Chief People Officer
  • David Phillips, MBA, Senior Vice President, Head of Quality
  • Samir Vattompadam, MS, Senior Vice President, Portfolio Strategy and Program Management
  • Daniella Beckman, Board of Directors
  • David Lubner, Board of Directors
  • Bill Lundberg, MD, Board of Directors
  • Fouad Namouni, MD, Board Of Directors
  • Matthew R. Patterson, Chairman, Board of Directors
  • Josh Resnick, MD, Board of Directors

Last updated: 2024-12-31

Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

Epoladerm, Probudur, Envelta, PES200, An Qlar, VRP324

Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company dedicated to developing drug-delivery systems and technologies for non-opioid, non-addictive pain management and treatments for central nervous system disorders.

Tags: Envelta, Epoladerm, Probudur, central nervous system, drug-delivery, non-opioid, pain management, pharmaceutical, preclinical

Symbol: VRPX

Recent Price: $0.45

Industry: Biotechnology

CEO: Mr. Jatinder Dhaliwal

Sector: Healthcare

Employees: 7

Address: 1055 Westlakes Drive, Berwyn, PA 19312

Phone: 610 727 4597

Last updated: 2024-12-31

Verastem, Inc.

Verastem, Inc. logo
Market Cap: Low
Employees: Low

VS-6766

Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for cancer treatment, with products such as VS-6766 and trials like RAMP 201 and 202 targeting various cancer types.

Tags: MEK, RAF, RAMP 201, RAMP 202, VS-6766, biopharmaceutical, cancer treatment, drug development

Symbol: VSTM

Recent Price: $3.67

Industry: Biotechnology

CEO: Mr. Daniel W. Paterson

Sector: Healthcare

Employees: 73

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 781 292 4200

Last updated: 2024-12-31

X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

mavorixafor

X4 Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases, with its lead product mavorixafor in advanced clinical trials.

Tags: CXCR4, biopharmaceutical, clinical trials, mavorixafor, rare diseases, therapeutics

Symbol: XFOR

Recent Price: $0.81

Industry: Biotechnology

CEO: Dr. Paula Ragan Ph.D.

Sector: Healthcare

Employees: 127

Address: 61 North Beacon Street, Boston, MA 02134

Phone: 857 529 8300

Last updated: 2024-12-31

Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

intravenous Tramadol

Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the acute/intensive care hospital setting. The company is advancing intravenous Tramadol, a synthetic dual-acting opioid, in Phase III clinical trials for post-operative acute pain treatment.

Tags: acute care, clinical trials, intensive care, intravenous Tramadol, opioids, pain management, pharmaceutical

Symbol: ATXI

Recent Price: $1.94

Industry: Biotechnology

CEO: Dr. Alexandra MacLean M.D.

Sector: Healthcare

Employees: 3

Address: 1140 Avenue of the America, New York, NY 10036

Phone: 781 652 4500

Leadership

  • Jay Kranzler, MD, PhD, Chairman of the Board of Directors
  • Alexandra MacLean, MD, Director
  • David Jin, Interim Chief Financial Officer
  • Scott A. Reines, MD, PhD, Interim Chief Medical Officer
  • Michael Ryan, MS, Vice President of Clinical Operations and Program Management
  • Alix MacLean, Chief Executive Officer
  • Lindsay A. Rosenwald, MD, Director
  • Neil Herskowitz, Director
  • Curtis Oltmans, Director
  • Faith Charles, Director

Last updated: 2024-12-31

Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

TERN-101, TERN-201, TERN-501, TERN-601

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity, incorporating products like TERN-101, TERN-201, TERN-501, and TERN-601.

Tags: NASH, biopharmaceutical, clinical trials, obesity, pharmaceutical research

Symbol: TERN

Recent Price: $7.15

Industry: Biotechnology

CEO: Ms. Amy L. Burroughs M.B.A.

Sector: Healthcare

Employees: 66

Address: 1065 East Hillsdale Boulevard, Foster City, CA 94404

Phone: 650 525 5535

Last updated: 2024-11-08